Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment

To better understand the resistance mechanism of non-small cell lung cancers (NSCLCs) to gefitinib, the metabolic profiles of gefitinib-resistant A549 cells and gefitinib-sensitive PC-9 cells were analyzed with a metabolomics analytical platform. A549 and PC-9 cells exhibited significant differences...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liang, Peng, Wen, Wu, Tianming, Deng, Pengchi, Zhao, Ying-Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085389/
https://www.ncbi.nlm.nih.gov/pubmed/30109143
http://dx.doi.org/10.1038/s41420-018-0086-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085389/
https://www.ncbi.nlm.nih.gov/pubmed/30109143
http://dx.doi.org/10.1038/s41420-018-0086-x

Ejemplares similares